<DOC>
	<DOCNO>NCT00838760</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability plasma pharmacokinetics ( pk ) ( i.e. , level TMC558445 circulate blood time ) increase single oral dos TMC558445 multiple increase oral dos follow single dose TMC310911 assess potential boost effect latter compound . In study , two investigational new drug involve , TMC558445 TMC310911 . The study amend follow : TMC558445 administer either twice day ( b.i.d . ) daily ( q.d. ) . A single 300 mg 600 mg dose TMC310911 administer fasted fed condition . The boost effect Darunavir investigate .</brief_summary>
	<brief_title>PEPI-TiDP23-C103 : First-in-Human Study Examine Safety , Tolerability , Plasma Pharmacokinetics Increasing Single Repeated Oral Doses TMC558445 Combined Single Day Dosing Oral TMC558445 Oral TMC310911 Also Oral Darunavir</brief_title>
	<detailed_description>This First-in-Human Phase I , double-blind ( neither physician patient know name assign study drug ) , randomize ( study medication assign chance ) , placebo-controlled trial TMC558445 examine safety , tolerability plasma pharmacokinetics increase single oral dos TMC558445 increase oral repeat dos TMC558445 , follow single day dose TMC558445 TMC310911 . This combination assess potential pharmacokinetic enhancement ( boost ) latter compound . TMC558445 use booster TMC310911 . The trial consist 2 part : single dose escalation multiple dose escalation part . The single dose escalation part consist 6 session . The single dose part include 18 healthy adult volunteer , divide 2 panel . In session , 6 healthy volunteer receive TMC558445 3 healthy volunteer receive placebo standard meal . Intake TMC558445/placebo take place Day 1 session 07:00 11:00 a.m . Single dose 40 , 100 , 200 , 400 , 800 , 1600 mg TMC558445/placebo administer alternate 2 panel . The trial stop early maximum tolerate dose reach . A washout period ( period treatment take view medication eliminate body start new treatment ) least 10 day respect consecutive TMC558445/placebo dosings . Once , food effect study fasted condition one previously study dos . The multiple dose escalation part trial start 200 mg dose find safe.This part trial include 27 healthy adult volunteer , divide 3 panel : 6 receive TMC558445 3 receive placebo . TMC558445/placebo administer 7 consecutive day . The treatment twice daily 07:00 11:00 a.m. 07:00 11:00 p.m . Volunteers receive single oral dose 300 mg TMC310911 Day 7 Day 1 Session XI ( washout period least 14 day ) . Dose escalation single multiple ascend dose regimen continue previous dose find safe . Pharmacokinetic profile TMC558445 determine max 72 h last intake per session . Pharmacokinetic profile TMC310911 determine 24 h. The expected duration investigational period single escalation dose part least 8 week least 3 week multiple escalation dose part . Safety tolerability evaluation record regular interval throughout trial . Blood urine sample take predefined timing well ECG measurement , vital sign ( blood pressure heart rate ) , physical examination . The study amend . In Panel 5 , TMC558445 may administer either twice daily daily TMC310911 may give 300 mg 600 mg single dose . Decision dose regimen , TMC310911 dose food condition make base result previous panel . The study amend follow : Panel 6 ( 9 adult volunteer ) , receive 800 mg Darunavir ( DRV ) day 7 combine TMC55844 give 7 day 200 mg daily dosis . After wash period 14 day participant receive Darunavir 800 mg alone . TMC558445 , TMC310911 placebo formulate oral drinkable solution . Part 1 consist single dose TMC558445/placebo 40 1600mg Day 1 session volume 2 20ml . Part 2 consist TMC558445/placebo twice daily Day 1 Day 7 max dose 200mg volume 5 ml + single intake 300 600mg TMC310911 ( 12/24ml ) / DRV 800mg morning Day 7 one session single dose TMC310911/ DRV Day 1 second session .</detailed_description>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Nonsmokers least 3 month prior selection Weight define Body Mass Index ( BMI , weight kg divide square height meter ) 18.0 30.0 kg/m2 , extremes include Informed Consent Form ( ICF ) sign voluntarily Able comply protocol requirement Healthy basis pretrial physical examination , medical history , result blood biochemistry hematology test , urinalysis , vital sign , 12lead electrocardiogram ( ECG ) Past history clinically significant heart arrhythmia ( extrasystoli , tachycardia rest ) Having baseline prolongation QTc interval &gt; 450 m , history risk factor Torsade de Pointes syndrome ( hypokalemia , family history long QT Syndrome ) Female , except postmenopausal 2 year , posthysterectomy postsurgical sterilization ( without reversal operation ) Currently active clinically relevant significant underlying gastrointestinal , cardiovascular , nervous system , psychiatric , metabolic , renal , hepatic , respiratory , inflammatory , infectious disease History clinically relevant skin disease allergy include drug allergy well</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>PEPI-TiDP23-C103</keyword>
	<keyword>PEPI-C103</keyword>
	<keyword>PEPI</keyword>
	<keyword>TMC558445</keyword>
	<keyword>TMC310911</keyword>
	<keyword>Darunavir , Healthy volunteer</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>HIV Infections</keyword>
</DOC>